Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Telehealth company Hims & Hers announced they will begin selling off-brand GLP-1 drugs similar to Ozempic and Wegovy at a ...
Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and ...
While the UK stock market is rising, the Diageo share price is falling. Here, Edward Sheldon looks at what’s going on with ...
As the global focus on health and weight management intensifies, Nestle has announced the launch of Vital Pursuit, a brand ...
There is no doubt that beauty culture penetrates all aspects of contemporary society. According to a Mckinsey & Company ...
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Semaglutide medications — including Ozempic and Wegovy — have been shown to reduce the risk of kidney failure and the risk of death among people with kidney disease and type 2 diabetes.
Giving obese children semaglutide could reduce their risk by 90 per cent. It comes after Diabetes UK revealed obesity has ...
THE ‘King Kong’ of fat jabs will be available on the NHS, health chiefs announced today. Mounjaro has already been rolled ...